Comparing Mobileye Global (NASDAQ:MBLY) & Aspire Biopharma (NASDAQ:ASBP)

Aspire Biopharma (NASDAQ:ASBP) and Mobileye Global (NASDAQ:MBLY) are both consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Aspire Biopharma and Mobileye Global, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1	0	0	0	1.00
Mobileye Global	2	9	10	2	2.52

Mobileye Global has a consensus price target of $12.16, suggesting a potential upside of 59.79%. Given Mobileye Global’s stronger consensus rating and higher possible upside, analysts clearly believe Mobileye Global is more favorable than Aspire Biopharma.

Volatility & Risk

Aspire Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Mobileye Global has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aspire Biopharma and Mobileye Global”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10,000.00	1,166.20	-$24.48 million	($69.62)	-0.12
Mobileye Global	$1.89 billion	3.37	-$392.00 million	($4.99)	-1.53

Aspire Biopharma has higher earnings, but lower revenue than Mobileye Global. Mobileye Global is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 13.3% of Mobileye Global shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 10.0% of Mobileye Global shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Aspire Biopharma and Mobileye Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Mobileye Global	-201.49%	0.70%	0.67%

Summary

Mobileye Global beats Aspire Biopharma on 11 of the 15 factors compared between the two stocks.

About Aspire Biopharma

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

About Mobileye Global

Mobileye Global Inc. develops and deploys advanced driver assistance systems (ADAS) and autonomous driving technologies and solutions worldwide. The company operates through Mobileye and Other segments. It offers Driver Assist comprising ADAS and autonomous vehicle solutions that covers safety features, such as real-time detection of road users, geometry, semantics, and markings to provide safety alerts and emergency interventions; Cloud-Enhanced Driver Assist, a solution for drivers with interpretations of a scene in real-time; Mobileye SuperVision Lite, a navigation and assisted driving solution; and Mobileye SuperVision, an operational point-to-point assisted driving navigation solution on various road types and includes cloud-based enhancements, such as road experience management. The company also provides Mobileye Chauffeur, a first-generation solution for eyes-off/hands-off driving with a human driver still in the driver’s seat; Mobileye Drive, a self-driving system comprising of radar and lidar subsystems, as well as collision avoidance systems, including Mobileye 8 Connect for light and medium-duty vehicles, and Mobileye Shield+ for large vehicles. It serves original equipment manufacturers. The company was founded in 1999 and is headquartered in Jerusalem, Israel. Mobileye Global Inc. operates as a subsidiary of Intel Overseas Funding Corporation.